Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
Danielle Rinck MDa, Elaine Siegfried MDb
aBeth Israel Deaconess Medical Center, Boston, MA | bSaint Louis University School of Medicine, St. Louis, MO
J Drugs Dermatol. 2022;21(8):897-899. doi:10.36849/JDD.6888
A previously healthy 3-year-old boy presented to our Pediatric Derm …
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
Danielle Rinck MDa, Elaine Siegfried MDb
aBeth Israel Deaconess Medical Center, Boston, MA | bSaint Louis University School of Medicine, St. Louis, MO
J Drugs Dermatol. 2022;21(8):897-899. doi:10.36849/JDD.6888
A previously healthy 3-year-old boy presented to our Pediatric Derm … Continue reading "Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy"
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Robyn Siperstein, an expert cosmetic dermatologist in Boca Raton and Boynton Beach, Fla. Knowing neck anatomy is vital not just for improved outcomes, but also for safety. Watch as Dr. Siperstein shares what you should know about neck anatomy and how that should influence your treatment … 
Dermatologic side effects are among the most frequent unexpected side effects of cancer treatments.1,2 Targeted therapies are associated with a lower incidence of systemic adverse events, but a higher incidence of dermatological AEs - including acneiform rash and pruritus.3
Skin toxicities can have a dramatic negative impact on QOL and overall success of treatment therapies.3
Skin toxicities oft … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Kalyani Marathe, director of the dermatology division at Cincinnati Children’s Hospital. Dr. Marathe shares serious pediatric skin issues including infections, drug reactions and congenital conditions. Watch and learn how to recognize and treat these serious issues, and how to know whe … 
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica …